Updated on February 15, 2024

·

Created on September 6, 2017

Q-POC

Upcoming Update

Q-POC is a portable rapid PCR testing device including SARS COV 2

Developed By
  1. QuantuMDx
Tested By
  • Stellenbosch University
  • University of Cape Town
Content Partners
Unknown

Author

Product Description

Q-POC is a solar-powered or wind-up handheld tool designed to diagnose, manage, monitor, and track infections and drug resistance. DNA-based diagnostics can be performed at point-of-care in 10-20 minutes with Q-POC. The device also includes GPS-enabled epidemiological surveillance. Q-POC is currently in a prototype stage and is expected to be commercialized soon. Single use test cartridges are being developed for Warfarin dosage, malaria and drug resistance, hospital acquired infections, and tumor profiling.)

Target SDGs

SDG 3: Good Health and Well-Being

Market Suggested Retail Price

$1,000.00

Target Users (Target Impact Group)

Small and Medium-sized Enterprises, Public Sector Agencies, NGOs

Distributors / Implementing Organizations

Currently unknown, but QuantuMDx is partnered with several NGOs, including FIND, the Bill and Melinda Gates Foundation, the Clinton Foundation, and the Global Good Fund.

Manufacturing/Building Method

QuantuMDx has partnered with Integrated Technologies Ltd. to manufacture batches of prototypes and eventually mass produce the final product.

Intellectural Property Type

Patent

User Provision Model

Unknown, as the product has not been commercialized yet.

Distributions to Date Status

N/A, product commercialization expected 2019

Consumables

Testing cassettes

Detection sensitivity

99%, 10 to 50 copies/mL

Sensitivity : No ‘indeterminate’ result

 

Indispensable equipment for function (Y/N)

Yes, testing cassettes

Maintenance or calibration required by user at time of use? (Y/N)

No

Number of Tests Performed

The Q-POC can currently generate diagnostics for  SARs COV 2

Power supply type: Continuous, Recharging only (V, time required, battery life), Other

Continuous power supply from Mains with 100-240V, 50-60Hz

and  Li-Ion 14.4V / 6.90Ah / 99.40Wh Battery

Time required for procedure (minutes)

approximately 30 minutes

Design Specifications

The Q-POC is a portable, battery-operated diagnostics device that can process blood, urine, sputum, tissue, and swabs and delivers results in 10-20 minutes. Results are displayed on a touchscreen and can be stored on the device, sent to a printer, or transferred to a computer or the Cloud via USB or WiFi. Globally distributed Q-POC devices will also geotag and anonymize pathogen data and send to the cloud for real-time disease and drug resistance monitoring.   [caption id="attachment_63588" align="alignnone" width="400"] Technical Specifications of Q-POC[/caption]

Product Schematics

Technical Support

Provided by the manufacturer

Replacement Components

Testing cassettes

Lifecycle

Unknown

Manufacturer Specified Performance Parameters

QuantuMDx seeks Q-POC can provide personalized medicine, be portable, provide a quick diagnosis, allow for geotagging an creating a network of data.

Vetted Performance Status

99% sensitivity and specificity to molecular results were claimed.

Safety

Unknown

Complementary Technical Systems

None

Academic Research and References

Dunning, L., Kroon, M., Hsiao, N., and Myer, L., 2017, Field Evaluation of HIV Point-of-Care Testing for Early Infant Diagnosis in Cape Town, South Africa, PloS One, 12(12), p. e0189226.

Vu, C., Chan, J., Todaro, M., Skafidas, S., and Kwan, P., 2015, Point-of-Care Molecular Diagnostic Devices: an Overview, Pharmacogenomics, 16(12), pp. 1399-1409.

Dorman, S., 2015, Advances in the Diagnosis of Tuberculosis: Current Status and Future Prospects, The International Journal of Tuberculosis and Lung Disease, 19(5), pp. 504-516.

Basha, I., Ho, E., 2017, Towards Multiplex Molecular Diagnosis—A Review of Microfluidic Genomics Technologies, Micromachines, 8(9), p. 266.

Compliance with regulations

QuantumDx plans to obtain CE marking for all of the Q-POC tests in the short term and then pursue a 510(k) submission with the US Food and Drug Administration.

Evaluation methods

Clinical trials planned in South Africa, sensitivity tests performed.

Other Information

None

Leave a Reply

Explore similar solutions

Agriculture

December 14, 2023

AFRIpads Menstrual Kit

Read Solution

Implemented by

AFRIpads

Agriculture

December 2, 2024

BioLite HomeStove

Read Solution

Implemented by

BioLite

Agriculture

February 29, 2024

CARC Hybrid Wheelchair

Read Solution

Implemented by

BRAC University

Agriculture

January 11, 2024

Caminos de Agua Ceramic filters

Read Solution

Implemented by

Caminos de Agua

Agriculture

January 17, 2024

Compartment Bag Test (CBT) Kit

Read Solution

Implemented by

Aquagenx

Agriculture

February 14, 2024

DFA Paper-based liver function test (AIDS, TB)

Read Solution

Implemented by

Diagnostics for all

Agriculture

September 23, 2023

Dispensers for Safe Water

Read Solution

Implemented by

Innovations for Poverty Action

Agriculture

November 10, 2023

Embrace Infant Warmer

Read Solution

Implemented by

Embrace Innovations

Agriculture

September 26, 2024

Freeplay FHRM

Read Solution

Implemented by

Ultrasound Technologies

Agriculture

January 2, 2024

Gadyen Dlo

Read Solution

Implemented by

Deep Springs International

All Solutions

Contribute to E4C's Library of Breakthrough Sustainable Development Technology Solutions

Suggest A Solution

Get more information about Solutions Library and its features.

Learn More

Have thoughts on how we can improve?

Give Us Feedback

Join a global community of changemakers.

Become A Member